Drug Pipeline Database & Screener

Over 1500 drug entries from over 400 biotech companies in Phase 2, 3 or NDA development.

Company SCREENER also available to filter through financial and clinical data. Financial filters include market cap, short ratio, price to book and relative volume, while you can also run a filter according to the development stage of the drug (e.g. Phase 2, PDUFA date).

N.B. The short ratio is the number of shares sold short divided by the average daily volume, also known as the number of "days to cover".

Drug pipeline data are updated at the end of each trading day. Click on the date for the source of the catalyst. 


Visit the FDA Calendar for  latest Biotech Stock Catalyst dates (PDUFA dates and clinical data readouts).

Alternatively, the BioPharmCatalyst Biotech Stocks page provides data on daily price and volume movers and information on individual companies.


Subscribe HERE to ensure you receive your weekly free copy of the BioPharmCatalyst Biotech Watchlist and/or our daily option of Biotech Price Movers and Pipeline Database updates. 

Financial data are delayed 15-35 minutes.


Showing 444 companies
Screener
Sort
Stage
Market Cap
Price
Short ratio
Relative Volume
Price to book
FDA Calendar
Company
Price
Change
Market Cap
Outstanding Shares
Short Ratio
Updated
$81.20
-0.04  -0.05%
$3.6 billion
44.2 million
0.23
08/28/2017
Tap to view 6 drugs
Drug Indication Stage News
Annexin V-128 Early Breast Cancer Phase 2 Phase 2 initiated September 2016
Annexin V-128 Rheumatoid arthritis and ankylosing spondylitis Phase 1/2 Ongoing
Apoptosis Necrosis Phase 2 Phase 2 initiated September 2016
Lutathera Inoperable progressive midgut NETs PDUFA CRL issued December 21, 2016. NDA to be resubmission announced July 27, 2017 with new PDUFA date January 26, 2018.
Somakit-TATE Neuroendocrine tumor diagnosis Approved Approved June 1, 2016.
Somakit-TOC Neuroendocrine cancers Positive opinion by EMA released in October 2016.
$93.61
-0.86  -0.91%
$149.4 billion
1.6 billion
2.01
10/30/2017
Tap to view 31 drugs
Drug Indication Stage News
ABBV-8E12 Progressive supranuclear palsy (PSP) Phase 2 Phase 2 initiation announced January 25, 2017. Estimated Primary Completion Date: May 2019
ABBV-8E12 Alzheimer's disease Phase 2 Phase 2 initiation announced January 25, 2017. Estimated Primary Completion Date: April 2020.
ABT-414 Recurrent glioblastoma (rGBM) Phase 1 Phase 1 data at ASCO. Oral Abstract 2003. June 4, 2017.
ABT-494 Psoriatic Arthritis Phase 3 Phase 3 trial to commenced 2017.
ABT-494 Crohn’s Disease Phase 2b Phase 2 positive data at DDW Meeting May 9, 2017. Phase 3 trial to be initiated later in 2017.
ABT-494 Atopic Dermatitis Phase 2b Phase 2b data released September 7, 2017 - primary endpoint met.
ABT-494 - SELECT-BEYOND Rheumatoid arthritis Phase 3 Phase 3 top-line released September 11, 2017. Endpoints met but with two patient deaths.
ABT-494 - SELECT-COMPARE Rheumatoid arthritis Phase 3 Phase 3 data due 2018.
ABT-494 (upadacitinib) - SELECT-NEXT Rheumatoid arthritis Phase 3 Phase 3 top-line data released June 7, 2017 - primary endpoints met.
Elagolix Uterine Fibroids Phase 3 Phase 3 initiated January 2016. Data due 2018.
Elagolix Endometriosis PDUFA priority review First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA filing announced September 6, 2017. Priority review announced October 27, 2017. Exact PDUFA date not announced. Estimate April 27, 2017 based on 6-month review.
Glecaprevir/Pibrentasvir (G/P) Hepatitis C virus (HCV) Approved Approval announced August 3, 2017.
Ibrutinib Relapsed or refractory MCL mantle cell lymphoma Approved Approved November 13, 2013.
Imbruvica Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy Approved Approved February 12, 2014.
Imbruvica Deletion 17p Approved Approved July 19, 2014.
IMBRUVICA Waldenström’s Macroglobulinemia Approved Approved January 29, 2015 - PCYC
Imbruvica Second-line Chronic graft-versus-host disease (GVHD) Approved Approval announced August 2, 2017.
Imbruvica Marginal zone lymphoma Approved sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Imbruvica - PHOENIX First-line Diffuse large B-cell lymphoma (DLBCL) Phase 3 Phase 3 data possibly due 2018.
Risankizumab Ulcerative colitis Phase 3 Phase 3 trial to be initiated 1H 2018.
Risankizumab Crohn’s Disease Phase 3 Phase 3 trial to commence 2H 2017.
Risankizumab Psoriasis Phase 3 Phase 3 data released October 26, 2017 - primary endpoints met.
Risankizumab Psoriatic Arthritis Phase 2b Phase 2b data due 2017.
Rova-T First-line small cell lung cancer (SCLC) maintenance Phase 3 Phase 3 trial to commence 2017.
Rova-T (TRINITY) Third-line Small Cell Lung Cancer Phase 2 Phase 2 pivotal data 2Q 2018.
Veliparib Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) Phase 3 Phase 3 trial did not meet primary endpoints - April 19, 2017.
Venclexta First-line Diffuse large B-cell lymphoma (DLBCL) Phase 3 Phase 3 trial planned.
Venclexta Follicular lymphoma (FL) Phase 3 Phase 3 trial planned.
Venclexta (MURANO) Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) Phase 3 Phase 3 data released September 18, 2017 - PFS primary endpoint met.
Venetoclax Relapsed or refractory multiple myeloma Phase 3 Phase 3 trial initiated July 2016. Data due 2019.
VIEKIRA PAK HCV - genotype 1 Approved Approved December 19, 2014.
$15.40
-0.70  -4.35%
$720.3 million
46.8 million
4.91
10/11/2017
Tap to view 3 drugs
Drug Indication Stage News
ABO-101 Recessive dystrophic epidermolysis bullosa (RDEB) Phase 2 Phase 2 enrollment commenced September 2016.
ABO-102 Sanfilippo syndrome type A (MPS IIIA) Phase 1/2 Phase 1/2 commencement of enrollment in pivotal trial expansion announced October 11, 2017.
EB-101 Recessive dystrophic epidermolysis bullosa (RDEB) Phase 1/2 Noted July 18, 2017 that Phase 3 trial will commence in early 2018.
$1.45
+0.00  0.00%
$17 million
11.8 million
1.07
11/10/2017
Tap to view 1 drug
Drug Indication Stage News
Gencaro - GENETIC-AF trial Chronic Heart Failure Phase 2b Phase 2b completion of enrollment announced August 16, 2017 - top-line data due late 1Q 2018.
$5.75
-0.10  -1.71%
$316.5 million
55.1 million
1.19
11/03/2017
Tap to view 4 drugs
Drug Indication Stage News
AB-423 (MAD) Hepatitis B (HBV) Phase 2 Phase 2 trial to be initiated 1Q 2018.
ARB-1467 Hepatitis B (HBV) Phase 2 Phase 2 Cohort 4 data released September 25, 2017 with detailed data due at AASLD in October 2017.
ARB-1467, tenofovir, and pegylated interferon Hepatitis B (HBV) Phase 2 Phase 2 interim data due 2H 2018 with full data due 2019.
TKM-PLK1 Hepatocellular carcinoma (HCC) Phase 1/2 Phase 1/2 data released July 2016. Intends to explore partnership opportunities to enable further study
$27.86
+0.22  0.80%
$3.5 billion
124.2 million
4.75
10/04/2017
Tap to view 5 drugs
Drug Indication Stage News
Pimavanserin Adjunctive treatment in patients with negative symptoms of schizophrenia Phase 2 Phase 2 initiated November 2016.
Pimavanserin Adjunctive treatment of schizophrenia Phase 3 Phase 3 initiated November 2016.
Pimavanserin Parkinson’s disease psychosis (PDP) Approved Approved April 29 2016
Pimavanserin - Harmony Alzheimer’s disease psychosis Phase 3 Phase 3 trial initiation announced October 4, 2017.
Pimavanserin - SERENE Alzheimer’s disease agitation Phase 2 Announced October 4, 2017 that trial will be discontinued.
$17.75
+0.46  2.66%
$13.1 million
739.4 thousand
1.88
09/25/2017
Tap to view 2 drugs
Drug Indication Stage News
EDSIVO Vascular Ehlers-Danlos Syndrome Phase 3 NDA filing 1H 2018.
Tovaxin (Tcelna) Secondary Progressive MS (SPMS) Phase 2b Phase 2b trial did not meet primary endpoint - October 28, 2016.
$3.43
-0.13  -3.65%
$472.9 million
137.9 million
6.80
11/15/2017
Tap to view 4 drugs
Drug Indication Stage News
ACH-4471 C3 glomerulopathy (C3G) Phase 2 Phase 2 interim data released November 14, 2017.
ACH-4471 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 Phase 2 initiation announced April 6, 2017. Interim data released August 8, 2017.
JNJ-4178 Hepatitis C (HCV) Phase 2a Janssen noted September 11, 2017 that no further development planned.
JNJ-4178 - OMEGA-1 Hepatitis C (HCV) Phase 2b Janssen noted September 11, 2017 that no further development planned.
$1.39
+0.07  5.30%
$16.6 million
11.9 million
0.17
11/10/2017
Tap to view 1 drug
Drug Indication Stage News
Cytisine Smoking cessation Phase 3 Phase 3 trial to be initiated mid-2018.
$10.61
-0.37  -3.37%
$603.9 million
56.9 million
13.83
11/13/2017
Tap to view 4 drugs
Drug Indication Stage News
ACI-24 (anti-Abeta vaccine) Alzheimer's disease-like characteristics in individuals with Down syndrome Phase 1/2 Phase 1/2 completion of recruitment of low-dose cohort noted September 12, 2017. Interim data due 2018.
Crenezumab - CREAD 1 Alzheimer’s disease Phase 3 Phase 3 trial commennced 1Q 2016. Phase 2 trial did not meet co-primary endpoints. IPO September 23, 2016. Data due 2020.
Crenezumab - CREAD 2 Alzheimer’s disease Phase 3 Second Phase 3 trial initiation announced February 28, 2017.
RO7105705 Alzheimer’s disease Phase 1b Phase 2 commencement of dosing announced November 2, 2017.
$22.90
+0.21  0.93%
$706.1 million
30.8 million
12.61
11/07/2017
Tap to view 4 drugs
Drug Indication Stage News
A-101 Seborrheic keratosis (SK) PDUFA PDUFA date is December 24, 2017
A-101 Common warts (verruca vulgaris) Phase 2b Phase 2 data released August 2016. Phase 2b trial initiation announced June 29, 2017. Top-line data due 2H 2018.
ATI-50001 Alopecia totalis and alopecia universalis Phase 2 Phase 2 data due by the end of 2018.
ATI-50002 Patchy alopecia areata Phase 2 Phase 2 trial to be initiated October 2017. Data due 1H 2018.
$2.08
+0.03  1.22%
$104.5 million
50.3 million
1.82
11/10/2017
Tap to view 3 drugs
Drug Indication Stage News
ARX-04 (SAP302) Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury Phase 3 Phase 3 data released August 15 2016
DSUVIA (ARX-04) Moderate-to-severe acute pain following a surgical procedure CRL CRL issued October 12, 2017.
Zalviso Post-operative pain following open abdominal surgery and hip or knee replacement surgery Phase 3 CRL Jul 26 2014. Additional clinical trial required. Data released August 1, 2017. NDA resubmission due YE 2017.
$1.27
+0.02  1.53%
$18.7 million
14.7 million
2.08
11/14/2017
Tap to view 1 drug
Drug Indication Stage News
CaPre Hypertriglyceridemia Phase 3 Phase 3 to begin treatment early 2018.
$7.88
-0.14  -1.75%
$738.3 million
93.7 million
3.49
11/14/2017
Tap to view 5 drugs
Drug Indication Stage News
NY-ESO T-cell therapy Synovial sarcoma - cancer Phase 1/2 Oral presentation at CTOS November 9, 2017.
NY-ESO T-cell therapy Ovarian cancer Phase 1/2 Reported no clinical responses October 2016. Intends to alter dosage to include fludarabine.
NY-ESO T-cell therapy Myxoid round cell liposarcoma (MRCLS) Phase 1/2 Poster at CTOS November 9, 2017.
NY-ESO T-cell therapy Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 initiated November 2015. Data are due 2017.
NY-ESO T-cell therapy + Pembrolizumab Myeloma Phase 1/2
$1.46
+0.00  0.00%
$5.7 million
3.9 million
0.33
02/22/2017
Tap to view 3 drugs
Drug Indication Stage News
MDX (Metadoxine Extended Release (MG01CI)) Adult ADHD Phase 3 Phase 3 data released January 17, 2017 - failed to meet primary endpoint.
MDX (Metadoxine Extended Release (MG01CI)) Pediatric ADHD Phase 2 Phase 2b data released March 2015. Secondary cognitive measures did not produce statistically significant results.
MDX (Metadoxine Extended Release (MG01CI)) Fragile X Syndrome Phase 2 Phase 2 trial did not meet endpoints - June 2015.
$2.85
-0.35  -10.94%
$73.5 million
25.8 million
3.58
06/27/2017
Tap to view 1 drug
$4.20
+0.05  1.20%
$131.7 million
31.4 million
3.36
10/10/2017
Tap to view 2 drugs
Drug Indication Stage News
APC-1000 Asthma/COPD Phase 2 Phase 3 planned.
Epinephrine Pre-filled Syringe (PFS) Emergency treatment of anaphylaxis. Approved CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.
$28.41
+0.72  2.60%
$647.1 million
22.8 million
8.22
09/07/2017
Tap to view 4 drugs
Drug Indication Stage News
ADS-4101 Partial onset seizures in patents with epilepsy Phase 1b Phase 1b top-line data released September 7, 2017.
ADS-5102 Multiple sclerosis (MS) Phase 2 Phase 2 data released early June 2016. Evaluating Phase 3 pathway.
ADS-5102 Levodopa-Induced Dyskinesia Approved Approval announced August 24, 2017.
Namzaric Moderate to severe dementia of the Alzheimer's type. Approved Approved December, 24 2014.
$8.80
-0.20  -2.22%
$684 million
77.7 million
12.62
10/31/2017
Tap to view 6 drugs
Drug Indication Stage News
ADU-S100 Solid tumors or lymphomas Phase 1b Phase 1b initiation of dosing announced September 26, 2017.
CRS-207 and GVAX Pancreas - ECLIPSE trial Pancreatic cancer Phase 2b Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial Pancreatic cancer Phase 2b Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
CRS-207 with KEYTRUDA Gastric cancer Phase 2 Phase 2 trial initiation noted June 29, 2017.
CRS-207 with pembrolizumab Mesothelioma - cancer Phase 2 Phase 2 trial to be initiated 2Q 2017 with early data due 2H 2017.
Epacadostat and CRS-207 - SEASCAPE Ovarian cancer Phase 1/2 Phase 1/2 dosing initiated March 2016.Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
$3.15
+0.00  0.00%
$141.9 million
45 million
1.36
11/09/2017
Tap to view 2 drugs
Drug Indication Stage News
ADVM-043 Alpha-1 Antitrypsin (A1AT) Deficiency Phase 1/2 Phase 1/2 preliminary data due 2H 2018.
AVA-101 Wet age-related macular degeneration (Wet-AMD) Phase 2a Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
$3.19
-0.05  -1.54%
$131 million
41.1 million
8.26
10/04/2017
Tap to view 7 drugs
Drug Indication Stage News
ADXS- DUAL Cervical cancer Phase 3 Phase 3 trial to be initiated 1H 2018.
ADXS-HER2 HER2-driven malignancies - cancer Phase 1b Phase 1b ongoing.
ADXS-PSA and Keytruda Castrate-resistant prostate cancer Phase 1/2 Completed the first two dose-escalation cohorts and launched the third dose-escalation cohort in April 2016. Part B combination portion of trial commenced October 2016. Preliminary data due 2018.
Axalimogene filolisbac Anal cancer (FAWCETT) Phase 2 Phase 2 initiated June 2016.
Axalimogene filolisbac - AIM2CERV Trial High-risk, locally advanced cervical cancer Phase 3 Announced Phase 3 first patient dosed - February 6, 2017. Enrollment continues as of August 2017. Data due 2020 or 2021.
Axalimogene filolisbac - GOG 0265 study Cervical cancer Phase 2 Phase 2 top-line data released October 24, 2016. Second stage was not completed due to the clinical hold in 2015.
Axalimogene filolisbac + durvalumab Recurrent or refractory HPV-associated cervical cancer and head & neck cancer Phase 1/2 Phase 1/2 ongoing.
$1.92
-0.02  -1.03%
$31.6 million
16.4 million
2.22
07/18/2017
Tap to view 2 drugs
$1.98
+0.03  1.28%
$88.2 million
44.7 million
1.53
11/06/2017
Tap to view 2 drugs
Drug Indication Stage News
AFM13 Hodgkin Lymphoma - Cancer Phase 2 Phase 2a full data due 2019.
AFM13 with Keytruda Hodgkin Lymphoma - Cancer Phase 1b Phase 1b poster at ASH December 9, 2017.
$3.70
-0.01  -0.27%
$370.7 million
100.2 million
4.65
10/21/2017
Tap to view 4 drugs
Drug Indication Stage News
AGEN2034 Solid tumors Phase 1/2 Phase 1/2 initiation announced April 20, 2017.
INCAGN1876 Solid tumors - cancer Phase 1/2 Phase 1/2 trial commenced June 2016
INCAGN1949 Solid tumors - cancer Phase 1/2 Phase 1/2 trial initiation announced November 30, 2016.
Shingrix Shingles Approved Approval announced October 20, 2017.
$59.64
+0.01  0.02%
$2.9 billion
48.8 million
14.35
11/01/2017
Tap to view 8 drugs
Drug Indication Stage News
AG-120 IDH1 mutant positive cholangiocarcinoma - cancer Phase 3 Phase 3 initiated December 2016.
AG-120 and VIDAZA - AGILE Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer Phase 3 Phase 3 initiated 2Q 2017.
AG-348 Pyruvate kinase deficiency Phase 2 Phase 2 first data released at EHA meeting June 2016. Updated data due at EHA June 24, 2017 with further data due at ASH December 10, 2017. Pivotal trials to be initiated 1H 2018.
Enasidenib (AG-221) - IDHENTIFY Refractory Acute myeloid leukemia (AML) - cancer Phase 3 Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of October 2017.
IDHIFA (enasidenib) - AG-221 Advanced hematologic malignancies with an IDH2 mutation Approved Approval announced August 1, 2017.
Ivosidenib Frontline Acute myeloid leukemia (AML) Phase 1 First data due from expansion trial at ASH December 11, 2017.
Ivosidenib R/R Acute Myeloid Leukemia (AML) Phase 1 First data due from expansion trial at ASH December 11, 2017.
Ivosidenib IDH1m Relapsed/Refractory AML - cancer Phase 3 NDA filing due by end of 2017.
$4.54
-0.20  -4.22%
$75.6 million
16.6 million
1.19
11/08/2017
Tap to view 3 drugs
Drug Indication Stage News
AEB1102 Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS) Phase 1 Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
AEB1102 Arginase I deficiency Phase 1/2 Phase 1/2 dosing in repeat dose part (Part 2) announced September 6, 2017. Top-line data due 2H 2018.
AEB1102 + KEYTRUDA Small cell lung cancer (SCLC) Phase 1/2 Phase 1/2 trial to be initiated 1Q 2018.
$174.88
+0.07  0.04%
$58.2 billion
332.6 million
1.81
11/13/2017
Tap to view 24 drugs
Drug Indication Stage News
ABICIPAR Diabetic macular edema (DME) Phase 3 Phase 3 trial to be initiated 2H 2017.
ABICIPAR Age-related macular degeneration (AMD) Phase 3 Phase 3 data due 2H 2018.
ABP 980 Herceptin biosimilar BLA Filing BLA filing announced July 31, 2017.
ATOGEPANT Prophylaxis (migraine) Phase 2b Phase 2b top-line data due 1H 2018.
AVYCAZ (ceftazidime and avibactam) Complicated Urinary Tract Infections (cUTI) Approved sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
Bimatoprost Androgenic Alopecia Phase 3 Phase 3 enrollment to be completed 2H 2018.
Botox Forehead lines Approved Approval (third indication) announced October 3, 2017.
Botox Depression Phase 2 Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
Brazikumab Crohn's disease Phase 2b Phase 2b data due 2018.
Brimo DDS Atrophic Age-related macular degeneration (AMD) Phase 2 Phase 2 top-line data due 2H 2017.
Cariprazine Major depressive disorder (MDD) Phase 3 Phase 3 data due 2H 2018.
Cariprazine Maintenance Treatment of Schizophrenia Approved Approval announced November 13, 2017.
Cenicriviroc (CVC) Nonalcoholic steatohepatitis (NASH) Phase 3 Phase 2 two year data due 2H 2017. Phase 3 trial has been initiated.
Cortisol Analog Dry Eye disease Phase 3 Phase 3 trial to be initiated 2H 2017.
ESMYA (ulipristal acetate) Uterine Fibroids PDUFA Phase 3 data released January 18, 2017 - endpoints met. PDUFA date 1H 2018 - exact date not provided.
JUVÉDERM VOLLURE Correction of moderate to severe facial wrinkles and folds Approved Approval announced March 20, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults Chronic idiopathic constipation (CIC) Approved sNDA approval announced January 26, 2017.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) Approved Approved September 14, 2017.
Oxymetazoline HCl cream 1.0% Facial Erythema (Redness) Associated with Rosacea Approved Approved January 19, 2017.
RAPASTINEL Major depressive disorder (MDD) Phase 3 Phase 3 initiated October 2016. Data due 2019.
RELAMORELIN Diabetic Gastroparesis Phase 3 Phase 3 to be initiated 2H 2017 with top-line data due 2020.
RORγt agonist Psoriasis Phase 2b Phase 2b trial to be initiated 2H 2017.
Sarecycline Severe acne vulgaris Phase 3 Phase 3 data released March 27 2017 - primary endpoints met. NDA filing due 2H 2017.
UBROGEPANT Acute (migraine) Phase 3 Phase 3 initiated July 2016. Data due 1H 2018.
$4.57
+0.10  2.24%
$156.2 million
34.2 million
1.28
07/27/2017
Tap to view 1 drug
$3.95
+0.15  3.95%
$71.5 million
18.1 million
1.84
09/13/2017
Tap to view 2 drugs
Drug Indication Stage News
AAV Gene Therapy CNGB3 Achromatopsia Phase 1/2 Phase 1/2 continues to enroll - September 2017.
rAAV-hRS1 X-linked retinoschisis (XLRS) Phase 1/2 Phase 1/2 completion of enrollment due 1Q 2018 with data due after the last patient has been followed for six months (est 3Q 2018).
$34.95
-0.33  -0.94%
$1.8 billion
50.9 million
5.26
11/06/2017
Tap to view 3 drugs
$11.83
-0.12  -1.00%
$501.5 million
42.4 million
9.83
10/26/2017
Tap to view 3 drugs
Drug Indication Stage News
C-Scape Complicated urinary tract infections (cUTI) due to multi-drug resistant (MDR) pathogens Phase 3 Phase 3 trial to be initiated 1H 2018.
Plazomicin Complicated urinary tract infections (cUTI) NDA Filing Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing announced October 26, 2017.
Plazomicin - CARE Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE) Phase 3 Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
$15.36
+0.23  1.52%
$726.1 million
47.3 million
7.47
11/09/2017
Tap to view 4 drugs
Drug Indication Stage News
Vadadustat - FO2RWARD Renal anemia Phase 2 Phase 2 data due by the end of 2018.
Vadadustat - INNO2VATE Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD) Phase 3 Phase 3 initiated August 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
Vadadustat - PRO2TECT Non-dialysis patients with anemia related to CKD (NDD-CKD) Phase 3 Phase 3 initiated January 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
Vadadustat - TRILO2GY Three-times-weekly dosing regimen for vadadustat Phase 3 Phase 3 trial to be initiated late 2017 or early 2018 with data due by the end of 2018.
$17.88
+0.08  0.45%
$1.2 billion
66.5 million
8.73
11/15/2017
Tap to view 7 drugs
Drug Indication Stage News
AKCEA-ANGPTL3-LRx Rare hyperlipidemias Phase 2 Phase 2 trial initiation announced November 13, 2017.
AKCEA-ANGPTL3-LRx Non-alcoholic fatty liver disease (NAFLD) Phase 2 Phase 2 trial to be initiated 2017.
AKCEA-APO(a)-LRx Hyperlipoproteinemia(a) and established cardiovascular disease Phase 2b Phase 2b initiation announced March 30, 2017. Data due 2018.
AKCEA-APOCIII-LRx Hyperlipoproteinemia(a) and established cardiovascular disease Phase 2b Phase 2b trial to be initiated 4Q 2017.
Volanesorsen Partial lipodystrophy rapidly Phase 3 Phase 3 initiated November 2015
Volanesorsen Familial partial lipodystrophy (FPL) Phase 3 Phase 3 initiated November 2015
Volanesorsen - APPROACH Familial chylomicronemia syndrome (FCS) PDUFA PDUFA date August 30, 2017.
$4.65
+0.27  6.16%
$54.8 million
11.8 million
1.53
10/11/2017
Tap to view 1 drug
Drug Indication Stage News
Coversin Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 Phase 2 interim data released April 24, 2017. Further update due at ASH December 9-12, 2017. Phase 3 program to commence 1Q 2018.
$25.99
+0.42  1.64%
$231.3 million
8.9 million
1.49
11/15/2017
Tap to view 1 drug
Drug Indication Stage News
A4250 Progressive familial intrahepatic cholestasis (PFIC) Phase 3 Phase 3 to be initiated by the spring of 2018.
$10.60
-0.05  -0.47%
$718.3 million
67.8 million
6.06
08/09/2017
Tap to view 3 drugs
$1.25
+0.03  2.46%
$86.4 million
69.1 million
3.16
02/26/2017
Tap to view 1 drug
Drug Indication Stage News
Iluvien Diabetic macular edema Approved CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
$127.51
+1.13  0.89%
$11.8 billion
92.7 million
5.67
11/16/2017
Tap to view 10 drugs
Drug Indication Stage News
ALN-CC5 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 1/2 Phase 1/2 initial data presented at ASH 2016.
ALN-CC5 (cemdisiran) Atypical hemolytic-uremic syndrome (aHUS) Phase 1/2 Phase 2 trial initiation announced September 26, 2017 with initial data due 2018.
ALN-GO1 Primary Hyperoxaluria Type 1 (PH1) Phase 1/2 Phase 1/2 initiated March 2016. Initial data released September 2016.
ALN-HBV Chronic hepatitis B virus (HBV) Phase 1/2 Phase 1/2 trial initiated July 2016. Ongoing as of February 2017.
ALN-TTRsc02 ATTR amyloidosis Phase 1 Phase 3 trial to be initiated 2018.
Fitusiran Hemophilia A and B Phase 2 Phase 2 trial suspended dosing due to fatal thrombotic event - noted September 7, 2017.
Fitusiran (ATLAS) Hemophilia Phase 3 Phase 3 program initiation announced July 7, 2017 with initial data due mid-late 2019. Dosing has yet to be initiated - noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Reinitiation targeted around YE 2017.
Givosiran Acute hepatic porphyrias Phase 3 Phase 3 trial initation announced November 7, 2017 with interim analysis data available in mid-2018.
Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR NDA Filing Phase 3 top-line data released September 20, 2017 - all endpoints met. Rolling NDA submission announced November 16, 2017, to be completed by end of 2017.
Revusiran ENDEAVOUR ATTR in patients with familial amyloidotic cardiomyopathy (FAC) Phase 3 Phase 3 trial discontinued October 2016.
$10.25
+0.23  2.30%
$142.3 million
13.9 million
1.23
07/31/2017
Tap to view 1 drug
Drug Indication Stage News
N91115 Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein Phase 2 Phase 2 data released February 24, 2017 - primary endpoint not met.
$12.30
+0.99  8.75%
$181 million
14.7 million
3.27
11/10/2017
Tap to view 2 drugs
Drug Indication Stage News
ALRN-6924 Peripheral T-cell lymphoma (PTCL) Phase 2a Phase 2a interim data due 1H 2018.
ALRN-6924 Solid tumors - cancer Phase 1/2 Phase 1 initial data presented at ASCO 2017. Completion of enrollment January 2017.
$110.87
+0.54  0.49%
$24.8 billion
223.4 million
2.49
11/01/2017
Tap to view 6 drugs
Drug Indication Stage News
ALXN1101 Molybdenum cofactor deficiency (MoCD) Type A Phase 2/3 Phase 2/3 enrolling.
ALXN1210 atypical Hemolytic Uremic Syndrome (aHUS) Phase 3 Phase 3 enrollment to be completed early 2018; Phase 3 trial in pediatric patients has also been initiated.
ALXN1210 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 1/2 Phase 3 data due 2Q 2018 (New Phase 1/2 data due at ASH December 11, 2017).
Eculizumab Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) Phase 3 Phase 3 enrollment to be completed in 2017 with data due mid-2018.
Eculizumab Refractory generalized myasthenia gravis (gMG) Approved Approval announced October 23, 2017.
SBC-103 MPS IIIB Phase 1/2 Phase 1/2 ongoing. No additional studies planned.
$14.00
-0.15  -1.06%
$495.2 million
35.4 million
10.89
09/16/2017
Tap to view 4 drugs
Drug Indication Stage News
Digoxin immune fab (DIF) Severe preeclampsia in pregnant women Phase 2/3 Phase 2/3 commencement of enrollment announced June 1, 2017.
Feraheme Adults with iron deficiency anemia (IDA) PDUFA PDUFA date February 2, 2018 for sNDA filing.
Makena - auto injector Reduce the risk of preterm birth in women with a singleton pregnancy PDUFA sNDA filing announced April 17, 2017. PDUFA date February 14, 2018. 10-month review despite initial expectations of a 6-month review.
Rekynda Hypoactive sexual desire disorder (HSDD) Phase 3 NDA filing due early 2018.
AMGN Amgen Inc.
$170.00
-0.77  -0.45%
$123.4 billion
725.9 million
2.75
10/09/2017
Tap to view 19 drugs
Drug Indication Stage News
ABP 710 REMICADE biosimilar - rheumatoid arthritis Phase 3 Phase 3 enrolling.
ABP 798 RITUXAN biosimilar - non-Hodgkin lymphoma Phase 3 Phase 3 enrolling. Estimate data 1H 2018 using clinicaltrials.gov data.
ABP 980 Herceptin biosimilar BLA Filing BLA filing announced July 31, 2017.
BLINCYTO Ph+ R/R ALL Approved PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
CNP 520 Alzheimer’s Disease Phase 2/3 Phase 2/3 ongoing. Expected completion 2023.
Corlanor Chronic Heart Failure Approved Approved April 15, 2015.
Erenumab Migraine PDUFA Phase 3 trial met primary endpoint September 2016. PDUFA date May 17, 2018.
EVENITY (Romosozumab) Osteoporosis CRL CRL issued July 16, 2017.
KYPROLIS (ARROW) Multiple Myeloma Phase 3 Phase 3 trial initiated June 2015.
KYPROLIS (ASPIRE) Relapsed Multiple Myeloma Phase 3 Phase 3 trial met primary endpoint. HR 79%.
KYPROLIS (ENDEAVOR) Relapsed Multiple Myeloma PDUFA Phase 3 trial met PFS endpoint - March 2015. Announced February 28, 2017 that interim analysis met secondary endpoint of overall survival (OS). PDUFA date for sNDA April 30, 2018.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) PDUFA Approved September 14, 2017.
Omecamtiv mecarbil GALACTIC-HF Acute heart failure Phase 3 Phase 3 commencement announced December 1, 2016. Enrollment to continue throughout 2017.
Parsabiv Secondary hyperparathyroidism (SHPT) Approved Approved February 7, 2017.
Prolia (denosumab) Glucocorticoid-induced osteoporosis (GIOP) PDUFA PDUFA date for sBLA filing May 28, 2017.
Repatha Cardiovascular disease PDUFA Phase 3 cardiovascular outcomes study data released March 17, 2017 - endpoints met but down on expectations. PDUFA date under priority review December 2, 2017.
Tezepelumab Asthma Phase 2b Phase 2b data released September 7, 2017 - primary endpoint met.
Vectibix (Panitumumab) Wild-Type RAS Metastatic Colorectal Cancer Approved sBLA approval announced June 29, 2017.
XGEVA Multiple Myeloma PDUFA sBLA filing announced April 4, 2017. Acceptance of filing announced June 19, 2017 - PDUFA February 3, 2018.
$1.40
+0.06  4.48%
$106.3 million
75.9 million
4.06
06/22/2017
Tap to view 2 drugs
$18.38
+0.23  1.27%
$845 million
46 million
14.31
02/23/2017
Tap to view 3 drugs
Drug Indication Stage News
Albuterol DPI Asthma Phase 2b
Naloxone Intranasal Opioid overdose CRL CRL announced February 21, 2017.
Primatene Mist (epinephrine inhalation aerosol) Asthma CRL CRL issued December 27, 2016.
$3.24
-0.18  -5.26%
$877.6 million
270.9 million
6.36
11/01/2017
Tap to view 1 drug
$76.64
+1.78  2.38%
$1.8 billion
23.5 million
1.17
11/07/2017
Tap to view 3 drugs
Drug Indication Stage News
ANB020 Moderate-to-severe adult atopic dermatitis Phase 2b Phase 2a positive data released October 10, 2017. Phase 2b trial to be initiated 1H 2018 with data due 2019.
ANB020 Severe adult eosinophilic asthma Phase 2a Phase 2a data due 2Q 2018.
ANB020 Severe adult peanut allergy Phase 2a Phase 2a data due 1Q 2018.
$53.39
-0.68  -1.26%
$782.8 million
14.7 million
15.01
10/25/2017
Tap to view 2 drugs
Drug Indication Stage News
Cingal Osteoarthritis Phase 3 Phase 3 completion of enrollment announced October 25, 2017. Trial to be completed 1H 2018.
Monovisc Osteoarthritis Approved Approved Feb 2014
$2.21
-0.03  -1.34%
$30.6 million
13.8 million
2.53
11/06/2017
Tap to view 4 drugs
Drug Indication Stage News
Blisibimod IgA nephropathy Phase 2 Phase 2 primary endpoint not met following interim analysis. Trial to continue. Top-line data released August 28, 2017.
Blisibimod Lupus Phase 3 Phase 3 trial did not meet endpoints - November 10, 2016.
Sollpura - RESULT Exocrine pancreatic insufficiency Phase 3 Phase 3 data due end 1Q 2018.
Sollpura (liprotamase) Cystic fibrosis who suffer from exocrine pancreatic insufficiency Phase 3 Top-line data released December 27, 2016 - missed primary endpoint.
$0.91
-0.01  -1.05%
$8.4 million
9.3 million
1.21
11/15/2017
Tap to view 1 drug
Drug Indication Stage News
AB-SA01 Chronic rhinosinusitis (CRS) Phase 1 Phase 2 planned.
$1.60
-0.02  -1.23%
$24.3 million
15.2 million
4.47
11/03/2017
Tap to view 2 drugs
Drug Indication Stage News
RayVa Secondary Raynaud's Phenomenon Phase 2b Phase 2b planned - seeking partnership.
Vitaros Erectile dysfunction PDUFA PDUFA date for NDA resubmission February 17, 2018.
$11.11
+0.28  2.59%
$260.7 million
23.5 million
7.64
08/08/2017
Tap to view 4 drugs
Drug Indication Stage News
AQX-1125 FLAGSHIP Chronic obstructive pulmonary disease (COPD) Phase 2 Phase 2 trail failed - July 2015
AQX-1125 KINSHIP Atopic dermatitis (AD) Phase 2 Phase 2 failed to demonstrate efficacy November 2015
AQX-1125 LEADERSHIP Bladder pain syndrome/interstitial cystitis (BPS/IC). Phase 3 Phase 2 trial did not meet endpoints - June 2015 but postive secondary endpoint data - August 2015. Phase 3 trial commenced September 2016. Data due 3Q 2018.
Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Phase 2 Phase 2 planned for 1Q 2018.
$3.57
+0.27  8.18%
$54.1 million
15.1 million
0.68
09/25/2017
Tap to view 2 drugs
Drug Indication Stage News
Linhaliq (Pulmaquin) Non-cystic fibrosis bronchiectasis (non-CF BE). PDUFA priority review PDUFA date under priority review January 26, 2018. Phase 3 data released December 1, 2016. One of two trials met primary endpoint.
Sumavel Migraine Approved Approval granted July 16, 2009.
$5.70
+0.10  1.79%
$270.9 million
47.5 million
0.85
11/07/2017
Tap to view 5 drugs
Drug Indication Stage News
RDX227675 Hyperkalemia Phase 3 Phase 3 trial initiation announced January 3, 2017.
RDX7675 Hyperkalemia Phase 2 Onset of action trial data due 4Q 2017.
Tenapanor Hyperphosphatemia in end-stage renal disease (ESRD) patients Phase 3 Phase 3 released February 15, 2017 - primary endpoint met. Second Phase 3 trial initiation due following feedback from FDA.
Tenapanor (T3MPO-1) Constipation-predominant irritable bowel syndrome (IBS-C) Phase 3 Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.
Tenapanor (T3MPO-2) Constipation-predominant irritable bowel syndrome (IBS-C) Phase 3 Phase 3 data released October 11, 2017. Primary endpoint met but with relatively high rates of diarrhea. NDA filing due 2H 2018.
ARGX argenx SE
$24.19
-0.15  -0.62%
$650 million
26.9 million
0.30
10/26/2017
Tap to view 4 drugs
Drug Indication Stage News
ARGX-110 Relapsed/refractory cutaneous T-cell lymphoma (CTCL) Phase 2 Phase 2 interim data due by ASH 2017 with top-line data due by the end of 2018.
ARGX-110 Acute myeloid leukemia (AML) Phase 1/2 Phase 1/2 interim data due by ASH 2017.
ARGX-113 Immune thrombocytopenia (ITP) Phase 2 Phase 2 data due 2H 2018.
ARGX-113 Myasthenia gravis (MG) Phase 2 Phase 2 data due 1Q 2018.
$1.65
+0.00  0.00%
$108.9 million
66 million
3.35
02/27/2017
Tap to view 2 drugs
Drug Indication Stage News
VIMOVO Gastric ulcers Approved Approved April 30, 2010.
YOSPRALA (PA32540/PA8140) Secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers Approved Approval announced September 15, 2016.
$26.53
-0.02  -0.08%
$1 billion
39.3 million
6.52
11/08/2017
Tap to view 8 drugs
Drug Indication Stage News
APD371 Pain associated with Crohn's disease Phase 2 Phase 2 data due 1Q 2018.
Etrasimod Primary biliary cholangitis (PBC) Phase 2 Phase 2 initiated 2017.
Etrasimod Pyoderma gangrenosum (PG) Phase 2 Phase 2 trial initiated March 2017.
Etrasimod Dermatological extraintestinal manifestations (EIM) in patients with inflammatory bowel disease (IBD) Phase 2 Phase 2 trial initiated March 2017.
Etrasimod Ulcerative colitis Phase 2 Phase 2 data due 1Q 2018.
Lorcaserin Obesity Approved Approved June 27, 2012.
Lorcaserin Smoking cessation Phase 2 Phase 2 initiated March 2014. Data released Nov 2014
Ralinepag Pulmonary Arterial Hypertension Phase 2 Phase 2 data released July 10, 2017. Primary endpoint met. Secondary missed.
$1.42
+0.09  6.77%
$123.7 million
87.1 million
2.95
08/04/2017
Tap to view 3 drugs
Drug Indication Stage News
ARQ 087 intrahepatic cholangiocarcinoma (iCCA) Phase 1/2 Phase 2 data at ASCO June 3, 2017 - ORR 21%. Phase 3 trial planned for 3Q 2017.
ARQ 092 Overgrowth Diseases Phase 1/2 Phase 1/2 trial has commenced enrollment - May 4, 2017.
Tivantinib (ARQ 197) METIV-HCC trial Previously treated Inoperable Hepatocellular Carcinoma cancer Phase 3 Phase 3 top-line data released February 17, 2017 - primary endpoint not met.
$11.52
+0.34  3.04%
$2.3 billion
197 million
8.25
11/13/2017
Tap to view 8 drugs
Drug Indication Stage News
ARRY 797 LMNA A/C-related dilated cardiomyopathy (DCM) Phase 2 Phase 2 data presented at the European Society of Cardiology on August 30, 2016. Phase 3 trial planned.
ARRY-382 and Keytruda Non-small cell lung cancer Phase 1/2 Phase 1/2 initial efficacy data presented in poster November 10, 2017 at SITC.
ARRY-520 (Filanesib) Refractory Multiple Myeloma Cancer Phase 2 Phase 2 interim data due 2016 but no plans to advance program
Binimetinib - COLUMBUS BRAF mutant melanoma cancer PDUFA Phase 3 data released September 26, 2016 met primary endpoint. PDUFA date June 30, 2018 - no Adcom anticipated.
Binimetinib - MILO Recurrent low-grade serous ovarian cancer (LGSOC) Phase 3 Phase 3 trial discontinued April 2016
Binimetinib (NEMO) NRAS melanoma - cancer Phase 3 PDUFA date originally set for June 30, 2017. Announed withdrawl of NDA filing - March 20, 2017.
Encorafenib and cetuximab - BEACON CRC BRAF-Mutant Colorectal Cancer Phase 3 Data at ESMO September 2017. ORR 41%. Median duration of treatment was 5.6 months.
Selumetinib - SELECT-1 Differentiated thyroid cancer Phase 3 Phase 3 trial did not meet its primary endpoint - August 2016
$3.70
+0.11  3.06%
$276.7 million
74.8 million
4.17
11/30/2016
Tap to view 3 drugs
Drug Indication Stage News
ARC-520 injection in combination with entecavir or tenofovir Chronic Hepititis B (HBV) Phase 2 Announced that development will be discontinued - November 29, 2016.
ARC-521 Chronic Hepititis B (HBV) Phase 1/2 Announced that development will be discontinued - November 29, 2016.
ARC-AAT Alpha-1 antitrypsin deficiency (AATD) Phase 2 Announced that development will be discontinued - November 29, 2016.
$35.54
+0.59  1.69%
$618.3 million
17.4 million
4.60
07/25/2016
Tap to view 1 drug
Drug Indication Stage News
VEN 307 (diltiazem cream) Anal fissures Phase 3 Phase 3 data from second trial did not meet primary endpoint - Feb 2014. Will not pursue future development
$36.94
+0.19  0.52%
$1.3 billion
36.4 million
2.23
11/16/2017
Tap to view 1 drug
Drug Indication Stage News
TransCon Growth hormone deficiency in children Phase 3 Phase 3 initiated August 2016. Enrollment continues as of November 2017.
$2.45
-0.05  -2.00%
$132.4 million
54 million
8.98
10/04/2017
Tap to view 3 drugs
Drug Indication Stage News
AST-OPC1 SCiSTAR Cervical spinal cord injury Phase 1/2 Phase 1/2 six and nine-month data released January 24, 2017. 10 and 20 million cell cohort 6-month top-line data due January 2018. Cohort 2 12-month data due later in 2017.
AST-VAC1 Acute myeloid leukemia (AML) Phase 2b Phase 2b planned for 2018.
AST-VAC2 Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 trial to be initiated 2017.
$1.84
+0.00  0.00%
$218.1 million
118.5 million
7.14
10/10/2017
Tap to view 2 drugs
$0.64
+0.01  1.74%
$51.1 million
80 million
1.01
11/12/2017
Tap to view 2 drugs
Drug Indication Stage News
Actimab-A Acute Myeloid Leukemia (AML) Phase 2 Phase 2 to initiated September 2016. Poster at ASH December 10, 2017 with top-line data due 1H 2018.
Iomab-B Hematopoietic Stem Cells Transplantation Phase 3 Phase 3 initiated June 2016. Enrollment to be completed by the end of 2018. Data due 2H 2019
$17.91
+0.36  2.05%
$1 billion
58 million
14.06
10/04/2017
Tap to view 2 drugs
Drug Indication Stage News
KX-01 Ointment Actinic keratosis Phase 3 Phase 3 patient recruitment announced September 25, 2017.
Oraxol Metastatic breast cancer Phase 3 Phase 3 interim data due 2017.
$0.33
-0.01  -1.54%
$8.8 million
26.5 million
0.20
01/10/2017
Tap to view 1 drug
Drug Indication Stage News
Fulvestrant Cuctal carcinoma in situ(DCIS) - invasive breast cancer Phase 2 Phase 2 enrollment to be completed by August 2017.
$14.60
+0.10  0.69%
$446.7 million
30.6 million
30.95
11/09/2017
Tap to view 4 drugs
Drug Indication Stage News
ATA 129 - ALLELE Epstein-Barr virus (EBV-PTLD) after solid organ transplant (SOT) Phase 3 Phase 3 trial planned YE 2017.
ATA 129 - MATCH Epstein-Barr virus (EBV-PTLD) after after hematopoietic cell transplant (HCT) Phase 3 Phase 3 trial planned YE 2017.
ATA129 and KEYTRUDA Nasopharyngeal carcinoma (NPC) Phase 1/2 Phase 1/2 trial to be initiated 2018.
PINTA 745 Protein-energy wasting Phase 2 Phase 2 endpoint not met December 2015
$1.84
-0.05  -2.65%
$288.3 million
156.7 million
0.81
10/21/2017
Tap to view 4 drugs
Drug Indication Stage News
Anturol Overactive bladder Approved Approved December 8, 2011.
Makena - auto injector Preterm birth PDUFA sNDA filing announced April 17, 2017. PDUFA date February 14, 2018. 10-month review despite initial expectations of a 6-month review
OTREXUP Rheumatoid arthritis (RA) Approved Approved Oct 14, 2013.
XYOSTED (testosterone enanthate) Testosterone deficiency CRL CRL issued October 20, 2017.
$5.14
-0.05  -0.96%
$431.6 million
84 million
6.40
11/15/2017
Tap to view 4 drugs
$9.23
+0.13  1.43%
$367 million
39.8 million
2.94
02/26/2017
Tap to view 5 drugs
Drug Indication Stage News
Akovaz Hypotension Approved Announced approval May 2 2016
Bloxiverz (neostigmine methylsulfate) Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery Approved Approved June 3, 2013.
Bloxiverz (neostigmine methylsulfate) Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery Approved Approved Jun 3 2013
Micropump Sodium Oxybate Excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy Phase 3 Phase 3 SPA agreed on - October 2016. Initiation of dosing announced December 16, 2016.
VAZCULEP (phenylephrine hydrochloride) Clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia Approved Approved June 30 2014.
$3.11
+0.05  1.63%
$368 million
118.3 million
2.75
11/07/2017
Tap to view 3 drugs
Drug Indication Stage News
Ficlatuzumab EGFR-mutated Non-small cell lung cancer (NSCLC) Phase 2 Announced September 12, 2016 that its Phase 2 trial has been discontinued
TIVO-3 - tivozanib Third line treatment of patients with renal cell cancer Phase 3 Phase 3 completion of enrollment noted June 20, 2017. Futility analysis released October 6, 2017 - trial to continue as planned. Top-line data due 1Q 2018.
Tivozanib + Opdivo Renal cell cancer (RCC) Phase 1/2 Phase 1/2 initiation of dosing announced March 22, 2017. Phase 2 part of trial initiation announced June 9, 2017.
$0.56
-0.01  -1.65%
$21.6 million
38.6 million
0.15
11/02/2017
Tap to view 4 drugs
Drug Indication Stage News
BTA074 5% topical gel Condyloma Phase 2 Phase 2 data due 2Q 2018.
BTA585 Respiratory syncytial virus (RSV) Phase 2a Phase 2a data released February 1, 2017 - primary endpoint not met.
Laninamivir Octanoate - IGLOO Adults with symptomatic influenza A or B infection Phase 2 Phase 2 initiated Jun 2013. Topline data did not meet the primary endpoint - July 2014
Vapendavir - SPIRITUS trial Human rhinovirus (HRV) Phase 2b Phase 2b top-line data released February 13, 2017 - primary endpoint not met.
$4.08
-0.02  -0.49%
$172.1 million
42.2 million
10.99
05/10/2017
Tap to view 2 drugs
Drug Indication Stage News
ANAVEX 2-73 Rett syndrome Phase 2 Phase 2 planned for 2017.
ANAVEX 2-73 Mild to moderate Alzheimer’s disease Phase 2a Phase 2a 12-month data released December 8, 2016. Trial is ongoing. Additional Phase 2/3 trial planned for 2017.
$97.28
-1.48  -1.50%
$3.1 billion
32 million
11.55
11/10/2017
Tap to view 2 drugs
Drug Indication Stage News
AVXS-101 Spinal muscular atrophy (SMA) Type 2 Phase 1/2 Phase 1/2 trial to be initiated 4Q 2017.
AVXS-101 STR1VE Spinal muscular atrophy (SMA) Type 1 Phase 3 Phase 3 trial has been initiated - noted November 9, 2017.
$4.99
-0.04  -0.80%
$537.5 million
107.7 million
2.39
11/03/2017
Tap to view 5 drugs
Drug Indication Stage News
Intepirdine Gait and Balance Impairments in Dementia Phase 2 Phase 2 data due January 2018.
Intepirdine - HEADWAY-DLB Dementia with Lewy bodies (DLB) Phase 2b Phase 2b data due January 2018.
Intepirdine - MINDSET Alzheimer's disease Phase 3 Phase 3 data released September 26, 2017 - primary endpoints not met.
Nelotanserin DLB patients experiencing REM Behavior Disorder (RBD) Phase 2 Phase 2 data due 1Q 2018.
Nelotanserin Visual hallucinations in subjects with Lewy body dementia Phase 2 Phase 2 preliminary data released February 13, 2017. Primary endpoint hit, secondary endpoints missed. Top-line data due January 2018.
$4.70
-0.20  -4.08%
$111.3 million
23.7 million
4.12
11/09/2017
Tap to view 5 drugs
Drug Indication Stage News
AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3 Phase 3 initiation contingent upon resources.
AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions Phase 3 Phase 3 commenced March 2016. Interim efficacy analysis due late December 2017 or early January 2018.
AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) Phase 3 Initiated July 2015. Interim efficacy analysis due late December 2017 or early January 2018.
AXS-05 ADVANCE-1 Agitation in patients with Alzheimer’s disease (AD) Phase 2/3 Phase 2/3 initiation announced July 17, 2017.
AXS-05 STRIDE-1 Treatment resistant depression Phase 3 Phase 3 initiated March 2016. Top-line data due 1Q 2018.
$33.46
-0.06  -0.18%
$84.7 billion
2.5 billion
4.15
11/15/2017
Tap to view 35 drugs
Drug Indication Stage News
Acalabrutinib Relapsed or Refractory Mantle Cell Lymphoma Approved Priority Review announced August 2, 2017. Approval announced October 31, 2017.